P2, N=26, Recruiting, University of Miami | Not yet recruiting --> Recruiting

P2, N=47, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting

P2, N=39, Active, not recruiting, University of Rochester | Recruiting --> Active, not recruiting

This disease exhibits a poor prognosis and responds poorly to standard R-CHOP therapy,highlighting the urgent need for novel treatments...ALA exerts potent anti-DEL activity by simultaneously targeting GSK3β in the Wnt pathway and directly inhibiting BCL2, leading to suppressed tumor proliferation and induced apoptosis. Our findings highlight ALA as a promising multi-targeting therapeutic candidate for DEL and propose a novel strategy against this refractory lymphoma.

P2, N=18, Recruiting, University of Washington | Not yet recruiting --> Recruiting

P4, N=136, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center

Rituximab can reduce the relapse rate in children with new-onset nephrotic syndrome and shows good safety. Its therapeutic effect is achieved by regulating the number and function of T cells and by modulating the anti-inflammatory effects of cytokines.

Clinicians should remain vigilant for rituximab-associated ILD, which, although uncommon, can progress rapidly and result in poor outcomes.

P2, N=34, Active, not recruiting, Washington University School of Medicine | Trial completion date: May 2031 --> Apr 2029 | Trial primary completion date: May 2026 --> Sep 2025

P2, N=360, Not yet recruiting, Hoffmann-La Roche

Treatment with rituximab, high-dose methotrexate, and focal radiotherapy was initiated...Liquid biopsy of the CSF provides a promising alternative for diagnosing PISCL. However, further studies are needed to validate the clinical utility of this diagnostic approach.